According to a new report published by Allied Market Research, titled, “central nervous disorders therapeutics market by disease, by distribution channel, and by age group: opportunity analysis and industry forecast, 2021–2030,” the central nervous disorders therapeutics market was valued at $117.55 million in 2020, and is projected to reach $232.29 million by 2030, registering a CAGR of 7.3% from 2021 to 2030.
The central nervous system (CNS) therapeutics market is expected to witness notable growth owing to rise in prevalence of the neurological conditions, rise in awareness and diagnosis of CNS disorders and surge in research and development by key players. Moreover, technological advancements in drug delivery are expected to provide lucrative opportunity for the growth of the market during the forecast period. On the contrary, the high cost of central nervous system (CNS) therapeutics limits the growth of the central nervous system (CNS) therapeutics market.
𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐆𝐫𝐚𝐩𝐡𝐬 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬 𝐇𝐞𝐫𝐞: https://www.alliedmarketresearch.com/request-sample/A305147
Recession Impact
- During economic downturns, there is a heightened focus on cost containment and efficient resource allocation. Recessions often result in budget cuts, impacting research funding from both public and private sectors.
- Moreover, it hampers investments in central nervous system therapeutics development, slowing down innovation and the introduction of advanced central nervous system therapeutics.
- However, despite budget constraints, the significance of healthcare research remains pivotal, especially during challenging times. Diseases and health concerns persist regardless of economic conditions, potentially leading to sustained demand for central nervous system therapeutics for medication packaging in the pharmaceutical sector.
𝐓𝐨𝐩 𝐂𝐞𝐧𝐭𝐫𝐚𝐥 𝐍𝐞𝐫𝐯𝐨𝐮𝐬 𝐒𝐲𝐬𝐭𝐞𝐦 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬
- Johnson and Johnson
- Eli Lilly and Company
- Merck and Co Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Hoffmann-La Roche AG
- Takeda Pharmaceutical Company Ltd.
- Viatris Inc.
- UCB Pharma
- Biogen, Inc.
The report provides a detailed analysis of these key players in the global central nervous system (CNS) therapeutics market. These players have adopted strategies such as product launch, product approval, acquisition, agreement, and partnership to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
𝐂𝐞𝐧𝐭𝐫𝐚𝐥 𝐍𝐞𝐫𝐯𝐨𝐮𝐬 𝐒𝐲𝐬𝐭𝐞𝐦 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧
Based on disease type, the neurodegenerative diseases segment held the largest market share in 2023, accounting for nearly two-fifths of the global central nervous system (CNS) therapeutics market revenue and is estimated to maintain its leadership status throughout the forecast period. This is attributed to a surge in prevalence of neurodegenerative disorders globally. Neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, Amyotrophic lateral sclerosis, have seen a rise in prevalence globally. The surge in the number of individuals suffering from neurodegenerative conditions resulted in increased demand for central nervous system therapeutics. Furthermore, the rise in geriatric population globally is expected to significantly contribute to the growth of the central nervous system (CNS) therapeutics market. However, CNS cancer segment is projected to manifest the highest CAGR of 9.8% from 2024 to 2033. This is attributed to the rising prevalence of CNS cancer worldwide.
Based on region, North America held the largest market share in terms of revenue in 2023, accounting for nearly half of the global central nervous system (CNS) therapeutics market revenue and is likely to dominate the market during the forecast period.
This is attributed to the strong presence of major key players such as Biogen Inc, Johnson and Johnson, Eli Lilly, and Company Inc. and Viatris Inc. In addition, the well-developed healthcare infrastructure and rise in prevalence of clinical depression and anxiety is expected to drive the growth of the central nervous system (CNS) therapeutics market in North America region.
However, Asia-Pacific is expected to witness the highest CAGR during the forecast period owing to rise in geriatric population and improving healthcare infrastructure. Furthermore, the large patient base in the Asia-Pacific region is expected to contribute significantly to the growth of the central nervous system (CNS) therapeutics market in Asia-Pacific region.
𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/purchase-enquiry/A305147
Our Market Research Solution Provides You Answer to Below Mentioned Question:
- Which are the driving factors responsible for the growth of market?
- Which are the roadblock factors of this market?
- What are the new opportunities, by which market will grow in coming years?
- What are the trends of this market?
- Which are main factors responsible for new product launch?
- How big is the global & regional market in terms of revenue, sales and production?
- How far will the market grow in forecast period in terms of revenue, sales and production?
- Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
- How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
- Which region has more opportunities?
By Region Outlook
North America
(U.S., Canada, Mexico)
Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Contact Details:
David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
